BiomX Inc. (NYSEAMERICAN:PHGE) Sees Significant Decline in Short Interest

BiomX Inc. (NYSEAMERICAN:PHGE) was the target of a significant decline in short interest during the month of January. As of January 15th, there was short interest totaling 51,433 shares, a decline of 20.4% from the December 31st total of 64,583 shares. Based on an average daily volume of 41,429 shares, the days-to-cover ratio is currently 1.2 days. Currently, 3.5% of the shares of the stock are sold short. Currently, 3.5% of the shares of the stock are sold short. Based on an average daily volume of 41,429 shares, the days-to-cover ratio is currently 1.2 days.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright increased their target price on BiomX to $26.00 and gave the company a “buy” rating in a research note on Tuesday, November 25th. One research analyst has rated the stock with a Buy rating, According to MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $26.00.

BiomX Trading Down 8.3%

PHGE traded down $0.52 on Tuesday, hitting $5.71. 97,934 shares of the company’s stock traded hands, compared to its average volume of 2,924,108. BiomX has a one year low of $1.50 and a one year high of $22.06. The company’s 50 day simple moving average is $3.23 and its 200-day simple moving average is $7.18. The firm has a market cap of $8.74 million, a price-to-earnings ratio of -0.22 and a beta of 1.66.

About BiomX

BiomX Inc is a clinical-stage biotechnology company that specializes in developing precision bacteriophage therapies to target pathogenic bacteria in the human microbiome. By harnessing the natural ability of bacteriophages to selectively infect and lyse harmful bacterial strains, BiomX aims to restore microbial balance without disrupting beneficial commensal organisms. The company’s platform integrates phage discovery, formulation and genetic engineering to create tailored phage cocktails for a range of microbiome-associated diseases.

The company’s pipeline includes lead clinical candidates for gastrointestinal disorders such as pouchitis and ulcerative colitis, as well as programs addressing dermatological indications including acne and atopic dermatitis.